By: King of Hemphill, et al. H.B. No. 428

(Senate Sponsor - Zaffirini)

(In the Senate - Received from the House April 13, 2021; April 13, 2021, read first time and referred to Committee on Business & Commerce; May 20, 2021, reported favorably by the following vote: Yeas 9, Nays 0; May 20, 2021, sent to printer.) Click here to see the committee vote

A BILL TO BE ENTITLED

AN ACT

relating to health benefit plan coverage for ovarian cancer testing and screening.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

SECTION 1. Section 1370.003(b), Insurance Code, is amended to read as follows:

(b) Coverage required under this section includes at a minimum:

(1) a CA 125 blood test; [and]

(2) a conventional Pap smear screening or a screening using liquid-based cytology methods, as approved by the United States Food and Drug Administration, alone or in combination with a test approved by the United States Food and Drug Administration for the detection of the human papillomavirus; and

(3) any other test or screening approved by the United States Food and Drug Administration for the detection of ovarian cancer.

SECTION 2. Section 1370.003, Insurance Code, as amended by this Act, applies only to a health benefit plan delivered, issued for delivery, or renewed on or after January 1, 2022. A health benefit plan delivered, issued for delivery, or renewed before January 1, 2022, is governed by the law as it existed immediately before the effective date of this Act, and that law is continued in effect for that purpose.

SECTION 3. This Act takes effect September 1, 2021.

* * * * *